Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.

Stocks | Futures | Watchlist | More
or

Kalvista Pharmaceuticals Inc (KALV)

Kalvista Pharmaceuticals Inc (KALV)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 470,431
  • Shares Outstanding, K 24,438
  • Annual Sales, $ 0 K
  • Annual Income, $ -46,240 K
  • 60-Month Beta 1.94
  • Price/Sales N/A
  • Price/Cash Flow N/A
  • Price/Book 1.92
Trade KALV with:

Options Overview

Details
  • Implied Volatility 87.26%
  • Historical Volatility 55.16%
  • IV Percentile 33%
  • IV Rank 4.32%
  • IV High 354.89% on 11/10/20
  • IV Low 75.18% on 07/16/21
  • Put/Call Vol Ratio 0.00
  • Today's Volume 12
  • Volume Avg (30-Day) 42
  • Put/Call OI Ratio 0.00
  • Today's Open Interest 1
  • Open Int (30-Day) 187

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 7 analysts offering recommendations.
Earnings Estimates - Current Qtr 07/31/21
See More
  • Average Estimate -0.73
  • Number of Estimates 4
  • High Estimate -0.66
  • Low Estimate -0.80
  • Prior Year -0.61
  • Growth Rate Est. (year over year) -19.67%

Price Performance

See More
Period Period Low Period High Performance
1-Month
18.17 unch
on 09/20/21
21.76 -16.52%
on 09/10/21
-0.24 (-1.30%)
since 08/20/21
3-Month
17.47 +4.01%
on 08/19/21
28.65 -36.58%
on 06/25/21
-9.86 (-35.18%)
since 06/18/21
52-Week
12.01 +51.29%
on 10/02/20
45.00 -59.62%
on 02/09/21
+4.38 (+31.76%)
since 09/18/20

Most Recent Stories

More News
KalVista Pharmaceuticals Announces the Lifting of FDA Clinical Hold for Phase 2 Trial of KVD824

--- Regulatory Submissions Complete for All Countries Participating in Trial -

KALV : 18.10 (-5.97%)
Canada CPI Due Next Week

Monday U.S. Featured Earnings Lennar Corporation (NYSE:LEN) (Q3) EPS projected for $3.24 cents, ...

UEPS : 4.50 (-1.10%)
UBA : 18.88 (-1.87%)
NSSC : 40.83 (-1.14%)
IBEX : 17.35 (-1.76%)
MLHR : 40.15 (-3.11%)
JKS : 43.89 (-8.71%)
ISR : 0.6251 (-8.07%)
LEN : 98.01 (-3.23%)
ET : 8.77 (-3.63%)
KALV : 18.10 (-5.97%)
HITI : 6.38 (-5.06%)
KalVista Pharmaceuticals Reports First Fiscal Quarter Results

--- KVD824 Phase 2 KOMPLETE Clinical Trial Enrolling -

KALV : 18.10 (-5.97%)
KalVista Pharmaceuticals Provides Progress Update on Phase 2 Clinical Trial of KVD824 for Oral Prophylactic Treatment of Hereditary Angioedema

--- Response Submitted to FDA on IND Requests for KVD824 Phase 2 -

KALV : 18.10 (-5.97%)
KalVista Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

KalVista Pharmaceuticals, Inc. (NASDAQ: KALV), today announced that the compensation committee of KalVista's board of directors granted four newly-hired employees inducement options to purchase an aggregate...

KALV : 18.10 (-5.97%)
KalVista Pharmaceuticals Provides Operational Update and Fiscal Year Financial Results

--- FDA Response Submission for KVD824 Phase 2 Clinical Hold Expected Q3 2021 -

KALV : 18.10 (-5.97%)
KalVista Pharmaceuticals Presents Data Showing Single On-Demand Treatment with Orally Administered KVD900 Significantly Slows Progression and Accelerates Resolution of Attacks in Patients with HAE

KalVista Pharmaceuticals, Inc. (NASDAQ: KALV), a clinical stage pharmaceutical company focused on the discovery, development, and commercialization of small molecule protease inhibitors, today announced...

KALV : 18.10 (-5.97%)
Canadian Investors Point to Jobs Data Next Week

Monday U.S. U.S. markets closed for Independence Day Tuesday U.S. Economic Lookahead Markit ...

TV.TO : 0.1700 (-5.56%)
TH.TO : 4.51 (-2.17%)
RCH.TO : 44.54 (-2.11%)
TV : 12.27 (-1.68%)
SGH : 46.46 (-4.76%)
MSM : 78.51 (-0.36%)
FIZZ : 51.90 (-0.61%)
WDFC : 225.42 (-0.87%)
KALV : 18.10 (-5.97%)
LEVI : 24.64 (-2.95%)
HELE : 229.06 (-2.11%)
ACCD : 43.31 (-4.62%)
GBX : 40.45 (-3.37%)
AZZ : 50.74 (-1.93%)
Analysts Estimate KalVista Pharmaceuticals, Inc. (KALV) to Report a Decline in Earnings: What to Look Out for

KalVista Pharmaceuticals, Inc. (KALV) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

KALV : 18.10 (-5.97%)
KalVista Pharmaceuticals to Present Data at the European Academy of Allergy and Clinical Immunology (EAACI)

KalVista Pharmaceuticals, Inc. (NASDAQ: KALV), a clinical stage pharmaceutical company focused on the discovery, development, and commercialization of small molecule protease inhibitors, today announced...

KALV : 18.10 (-5.97%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 100% Sell with a Strongest short term outlook on maintaining the current direction.

Long term indicators fully support a continuation of the trend.

See More Share

Business Summary

KalVista Pharmaceuticals, Inc. is a pharmaceuticals company. It engages in discovery, development and commercialization of small molecule protease inhibitors for diseases with significant unmet need. Its product portfolio consist hereditary angioedema and diabetic macular edema, KVD818 and KVD001, which...

See More

Key Turning Points

3rd Resistance Point 20.61
2nd Resistance Point 20.29
1st Resistance Point 19.77
Last Price 18.10
1st Support Level 18.93
2nd Support Level 18.61
3rd Support Level 18.09

See More

52-Week High 45.00
Fibonacci 61.8% 32.40
Fibonacci 50% 28.51
Fibonacci 38.2% 24.61
Last Price 18.10
52-Week Low 12.01

See More

Want to use this as
your default charts setting?
Learn about our Custom Templates
Switch the Market flag
above for targeted data.
Open the menu and switch the
Market flag for targeted data.
Get Streaming Chart Updates
Switch your Site Preferences
to Interactive Chart
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar